002099 海翔药业
已收盘 07-03 15:00:00
资讯
新帖
简况
海翔药业（002099）披露股份回购进展公告，7月1日股价上涨2.84%
证券之星 · 07-01
海翔药业（002099）披露股份回购进展公告，7月1日股价上涨2.84%
海翔药业：公司已于2026年6月25日开展首次回购
证券之星 · 06-30
海翔药业：公司已于2026年6月25日开展首次回购
海翔药业（002099）披露首次回购公司股份公告，6月26日股价下跌3.53%
证券之星 · 06-26
海翔药业（002099）披露首次回购公司股份公告，6月26日股价下跌3.53%
海翔药业（002099）披露回购股份事项前十名股东持股情况，6月24日股价下跌3.01%
证券之星 · 06-24
海翔药业（002099）披露回购股份事项前十名股东持股情况，6月24日股价下跌3.01%
海翔药业：通过优化生产工艺、精细化管理流程等措施，持续推进降本增效工作
证券之星 · 06-24
海翔药业：通过优化生产工艺、精细化管理流程等措施，持续推进降本增效工作
海翔药业(002099.SZ)拟1.5亿元至3亿元回购公司股份
智通财经 · 06-22
海翔药业(002099.SZ)拟1.5亿元至3亿元回购公司股份
海翔药业：公司始终立足主业，聚焦市场需求，致力于提升经营质量，不断夯实基本面价值
证券之星 · 06-18
海翔药业：公司始终立足主业，聚焦市场需求，致力于提升经营质量，不断夯实基本面价值
海翔药业：公司参投的寓鑫基金投资项目涉及航天航空、医药研发、高端设备制造、芯片制造（已退出）等领域
证券之星 · 06-18
海翔药业：公司参投的寓鑫基金投资项目涉及航天航空、医药研发、高端设备制造、芯片制造（已退出）等领域
海翔药业：2026年一季度公司染料板块利润同比增长
证券之星 · 06-08
海翔药业：2026年一季度公司染料板块利润同比增长
海翔药业：截至5月29日公司股东人数为34563人
证券之星 · 06-05
海翔药业：截至5月29日公司股东人数为34563人
海翔药业：公司连续两年推出回购股份计划
证券之星 · 06-04
海翔药业：公司连续两年推出回购股份计划
海翔药业（002099）披露为子公司提供担保的进展公告，5月28日股价上涨1.12%
证券之星 · 05-28
海翔药业（002099）披露为子公司提供担保的进展公告，5月28日股价上涨1.12%
海翔药业：截至5月20日公司股东人数为35190人
证券之星 · 05-25
海翔药业：截至5月20日公司股东人数为35190人
海翔药业：目前双方合作正常开展
证券之星 · 05-25
海翔药业：目前双方合作正常开展
海翔药业(002099.SZ)参投公司创新药注射用重组巴曲酶获得药物临床试验批准
智通财经 · 05-22
海翔药业(002099.SZ)参投公司创新药注射用重组巴曲酶获得药物临床试验批准
海翔药业：公司连续两年推出回购股份计划
证券之星 · 05-20
海翔药业：公司连续两年推出回购股份计划
海翔药业（002099）披露2025年度股东会决议公告，5月19日股价下跌1.7%
证券之星 · 05-19
海翔药业（002099）披露2025年度股东会决议公告，5月19日股价下跌1.7%
海翔药业：不存在关联方资金占用、违规担保情形
证券之星 · 05-15
海翔药业：不存在关联方资金占用、违规担保情形
海翔药业：公司目前生产经营活动正常有序
证券之星 · 05-15
海翔药业：公司目前生产经营活动正常有序
海翔药业：公司严格按照相关法律法规进行信息披露
证券之星 · 05-15
海翔药业：公司严格按照相关法律法规进行信息披露
暂无数据
公司概况
公司名称：
浙江海翔药业股份有限公司
所属行业：
医药制造业
上市日期：
2006-12-26
主营业务：
浙江海翔药业股份有限公司的主营业务是原料药及医药中间体、染料及染颜料中间体的研发、生产和销售。公司的主要产品是蒽醌系列染料产品、中间体。公司企业技术中心被认定为“国家级企业技术中心”，拥有国家级博士后工作站，已承担完成国家级项目14项，省级项目35项，拥有国内发明专利67项、PCT专利4项，荣获浙江省级科技奖项11项。
发行价格：
11.56
{"stockData":{"symbol":"002099","market":"SZ","secType":"STK","nameCN":"海翔药业","latestPrice":5.47,"timestamp":1783062189000,"preClose":5.39,"halted":0,"volume":20396119,"delay":0,"changeRate":0.0148,"floatShares":1617000000,"shares":1619000000,"eps":-0.0457,"marketStatus":"已收盘","change":0.08,"latestTime":"07-03 15:00:00","open":5.43,"high":5.52,"low":5.29,"amount":110000000,"amplitude":0.0427,"askPrice":5.47,"askSize":1858,"bidPrice":5.46,"bidSize":733,"shortable":0,"etf":0,"ttmEps":-0.0457,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":5.39,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":5.93,"lowLimit":4.85,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1618715253,"isCdr":false,"pbRate":1.77,"roa":"--","roe":"0.53%","epsLYR":-0.06,"committee":-0.505543,"marketValue":8854000000,"turnoverRate":0.0126,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-07-06。","floatMarketCap":8844000000},"requestUrl":"/m/hq/s/002099/tweets","defaultTab":"tweets","newsList":[{"id":"2648541606","title":"海翔药业（002099）披露股份回购进展公告，7月1日股价上涨2.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648541606","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648541606?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:36","pubTimestamp":1782916574,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，海翔药业报收于5.43元，较前一交易日上涨2.84%，最新总市值为87.9亿元。该股当日开盘5.25元，最高5.6元，最低5.15元，成交额达1.58亿元，换手率为1.83%。近日，浙江海翔药业股份有限公司披露《关于股份回购进展情况的公告》。公告显示，公司于2026年6月22日召开董事会，审议通过回购股份方案，拟使用自有/自筹资金以集中竞价交易方式回购公司股份，用于未来股权激励或员工持股计划。回购进展符合相关法规及既定方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0192","BK0239","BK0028","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647794556","title":"海翔药业：公司已于2026年6月25日开展首次回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2647794556","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647794556?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:53","pubTimestamp":1782823988,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业06月30日在投资者关系平台上答复投资者关心的问题。贵公司是否存在炒自家股票，低买高卖等行为？海翔药业回复：您好，公司已于2026年6月25日开展首次回购，内容详见《关于首次回购公司股份的公告》。在实际操作中，公司将综合考虑股价表现、资金安排及市场环境等因素，审慎把握回购时机，稳步推进回购工作，切实维护公司价值与全体股东合法权益。感谢您对公司的关注！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000043958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","002099","BK0192","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646551513","title":"海翔药业（002099）披露首次回购公司股份公告，6月26日股价下跌3.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646551513","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646551513?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:50","pubTimestamp":1782467459,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，海翔药业报收于5.19元，较前一交易日下跌3.53%，最新总市值为84.01亿元。该股当日开盘5.37元，最高5.45元，最低5.04元，成交额达1.62亿元，换手率为1.93%。公司于近日披露《关于首次回购公司股份的公告》。本次回购符合相关法律法规及公司董事会审议通过的回购方案。公司后续将在回购期限内根据市场情况继续实施回购计划，并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600033095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","002099","BK0192","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645819709","title":"海翔药业（002099）披露回购股份事项前十名股东持股情况，6月24日股价下跌3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645819709","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645819709?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:30","pubTimestamp":1782311432,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘，海翔药业报收于5.16元，较前一交易日下跌3.01%，最新总市值为83.53亿元。该股当日开盘5.37元，最高5.38元，最低5.16元，成交额达1.03亿元，换手率为1.22%。近日，浙江海翔药业股份有限公司发布《关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告》。其中，浙江东港实业有限公司持股523,982,587股，占总股本32.37%；公司回购专用证券账户持有54,212,531股，占总股本3.35%，未列入前十名股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400044081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0192","BK0188","BK0239","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645386082","title":"海翔药业：通过优化生产工艺、精细化管理流程等措施，持续推进降本增效工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2645386082","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645386082?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:07","pubTimestamp":1782284840,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，针对主业药方面严重亏损的事实是否有具体的转亏为盈的方案？药方面连续亏损并且在加剧亏损，是否有考虑砍掉一部分业务用于减亏！？谢谢。海翔药业回复：您好，公司致力于通过优化生产工艺、精细化管理流程等措施，持续推进降本增效工作，降低运营成本，以改善盈利能力，进一步提升核心竞争力。同时，公司还通过外延合作、产业基金投资等方式探索创新药领域机遇。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400022198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0192","BK0239","BK0028","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645256026","title":"海翔药业(002099.SZ)拟1.5亿元至3亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645256026","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645256026?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:23","pubTimestamp":1782123822,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业(002099.SZ)发布公告，公司拟使用自有/自筹资金以集中竞价方式回购公司部分A股股票，在未来适宜时机用于股权激励或者员工持股计划。回购总金额为不低于1.5亿元(含)，不超过3亿元(含)，回购价格不超过8.55元/股(含)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","BK0077","BK0239","002099","BK0192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644779496","title":"海翔药业：公司始终立足主业，聚焦市场需求，致力于提升经营质量，不断夯实基本面价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2644779496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644779496?lang=zh_cn&edition=full","pubTime":"2026-06-18 11:34","pubTimestamp":1781753692,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，公司主业药方面连续亏损且亏损扩大，公司是否有具体的措施改善主业的亏损情况？主业连续亏损股价连续暴跌，如何保障投资者权益？请明确说明，谢谢。海翔药业回复：您好，公司始终立足主业，聚焦市场需求，致力于提升经营质量，不断夯实基本面价值。二级市场股价波动受多种因素影响，与宏观环境、政策因素、行业经营状况及资本市场风格等综合情况密切相关，敬请注意投资风险。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800017186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0192","BK0188","BK0028","BK0077","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644779424","title":"海翔药业：公司参投的寓鑫基金投资项目涉及航天航空、医药研发、高端设备制造、芯片制造（已退出）等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2644779424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644779424?lang=zh_cn&edition=full","pubTime":"2026-06-18 11:34","pubTimestamp":1781753685,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司的投资基金有没有涉及芯片半导体相关企业？海翔药业回复：您好，公司参投的寓鑫基金投资项目涉及航天航空、医药研发、高端设备制造、芯片制造（已退出）等领域。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800017182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","BK0077","BK0192","BK1161","09939","159813","BK0188","BK0028","BK1515","BK1574","159208","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641102598","title":"海翔药业：2026年一季度公司染料板块利润同比增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2641102598","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641102598?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:09","pubTimestamp":1780906147,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业06月08日在投资者关系平台上答复投资者关心的问题。海翔药业回复：您好，公司医药板块和染料板块收入分别约占7成和3成。2026年一季度公司染料板块利润同比增长，但医药板块受市场价格下降以及销售产品结构影响出现亏损，拖累公司2026年第一季度经营业绩。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800019770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0239","BK0077","BK0028","002099","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641975195","title":"海翔药业：截至5月29日公司股东人数为34563人","url":"https://stock-news.laohu8.com/highlight/detail?id=2641975195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641975195?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:48","pubTimestamp":1780620499,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问：咨询一下目前美罗培南、克林霉素等原料药销售情况及公司到5月31日的股东人数海翔药业回复：您好，公司经营情况敬请关注后续披露的定期报告。截至5月29日公司股东人数为34563人。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500005649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0192","BK0188","BK0239","BK0028","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640150303","title":"海翔药业：公司连续两年推出回购股份计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2640150303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640150303?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:48","pubTimestamp":1780577303,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，贵司内部可以看到贵司二级市场的股价吧，对于贵司股价连续暴跌有何感想？连续暴跌有没有内查原因？是否有具体的市值管理方案？谢谢。海翔药业回复：您好，二级市场股价波动受多种因素影响，与宏观环境、政策因素、行业经营状况及资本市场风格等综合情况密切相关，敬请注意投资风险。公司始终立足主业，聚焦市场需求，致力于提升经营质量，不断夯实基本面价值。公司连续两年推出回购股份计划，维护公司全体股东利益。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400039291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","002099","BK0028","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638944946","title":"海翔药业（002099）披露为子公司提供担保的进展公告，5月28日股价上涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638944946","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638944946?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:55","pubTimestamp":1779980112,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，海翔药业报收于5.41元，较前一交易日上涨1.12%，最新总市值为87.57亿元。近日，浙江海翔药业股份有限公司与汇丰银行（中国）有限公司重新签署《保证书》，继续为合并报表范围内子公司港翔国际控股（香港）有限公司提供880万美元的连带责任担保，担保额度较此前减少770万美元，担保期限为1年。本次担保为原担保展期。截至2026年5月27日，公司对子公司担保总额为28,468.02万元，担保余额为6,129.63万元，无逾期对外担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800043629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","002099","BK0028","BK0188","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638351535","title":"海翔药业：截至5月20日公司股东人数为35190人","url":"https://stock-news.laohu8.com/highlight/detail?id=2638351535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638351535?lang=zh_cn&edition=full","pubTime":"2026-05-25 15:45","pubTimestamp":1779695110,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司到五月二十日的股东人数，谢谢海翔药业回复：您好，截至5月20日公司股东人数为35190人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500016997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0028","BK0239","BK0188","BK0077","BK0192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638953300","title":"海翔药业：目前双方合作正常开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2638953300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638953300?lang=zh_cn&edition=full","pubTime":"2026-05-25 15:39","pubTimestamp":1779694746,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请详细说明和万邦德的合作进展和现状？谢谢。海翔药业回复：您好，根据双方签订的《创新药合作协议》：万邦德以自有团队和资源，具体实施WP205产品研发、上市、授权、销售等各项工作。公司按照约定提供资金并取得相关收益权。目前双方合作正常开展。感谢您对公司的关注！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500016102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0192","BK0239","BK0188","BK0028","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637391887","title":"海翔药业(002099.SZ)参投公司创新药注射用重组巴曲酶获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637391887","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637391887?lang=zh_cn&edition=full","pubTime":"2026-05-22 15:45","pubTimestamp":1779435906,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业 发布公告，公司近日收到旗下产业基金管理人北京国信中数投资管理有限公司出具的《通知函》。公司获悉北京国信海翔股权投资合伙企业参投公司北京格瑞特森生物医药科技有限公司自主研发的创新生物药注射用重组巴曲酶收到国家药品监督管理局正式核发的《药物临床试验批准通知书》，同意本品开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","159992","BK1574","BK0239","06978","BK0077","BK1161","002099","BK0188","BK0192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636479418","title":"海翔药业：公司连续两年推出回购股份计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2636479418","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636479418?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:52","pubTimestamp":1779281564,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业05月19日在投资者关系平台上答复投资者关心的问题。公司连续两年推出回购股份计划，维护公司全体股东利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000041304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","BK0077","BK0239","002099","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636585710","title":"海翔药业（002099）披露2025年度股东会决议公告，5月19日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636585710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636585710?lang=zh_cn&edition=full","pubTime":"2026-05-19 22:44","pubTimestamp":1779201855,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，海翔药业报收于5.79元，较前一交易日下跌1.7%，最新总市值为93.72亿元。该股当日开盘5.84元，最高5.93元，最低5.68元，成交额达1.28亿元，换手率为1.36%。近日，浙江海翔药业股份有限公司披露《2025年度股东会决议公告》。公告显示，公司于2026年5月19日召开2025年度股东会，审议通过了《2025年度董事会工作报告》《2025年度财务决算报告》《2025年年度报告及摘要》《2025年度利润分配预案》等12项议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900044218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0239","BK0028","BK0188","BK0077","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706998","title":"海翔药业：不存在关联方资金占用、违规担保情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635706998?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:18","pubTimestamp":1778829502,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司账面3.7亿元存疑资金的核查目前进展如何？是否存在关联方资金占用、违规担保情形？后续计划何时完成全面核查并向市场公开详细说明？海翔药业回复：您好！公司审计机构天健会计师事务所（特殊普通合伙）已对公司2025年度财务报告和内部控制情况出具了标准无保留意见的审计报告，不存在您所述情形，请勿揣测。感谢您对公司关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500021789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0239","BK0188","BK0192","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706620","title":"海翔药业：公司目前生产经营活动正常有序","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706620","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635706620?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:15","pubTimestamp":1778829322,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业05月15日在投资者关系平台上答复投资者关心的问题。咨询一下目前公司的主要产品美罗培南、克林霉素等原料药价格有没有企稳回升。活性染料连续涨价，公司目前的产能利用率是多少，是否比以前提升。公司目前生产经营活动正常有序，在手订单储备与产能利用率相匹配。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500021758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002099","BK0028","BK0188","BK0239","BK0192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706317","title":"海翔药业：公司严格按照相关法律法规进行信息披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635706317?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:12","pubTimestamp":1778829139,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价连续大跌，是否有未披露的负面消息？公司股价连续大跌的情况下，有没有具体的市值管理方案和举措？如果保障投资者利益？海翔药业回复：您好，公司严格按照相关法律法规进行信息披露，不存在应披露而未披露事项。二级市场股价波动受多种因素影响，与宏观环境、政策因素、行业经营状况及资本市场风格等综合情况密切相关，敬请注意投资风险。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500021748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0192","BK0188","BK0239","BK0028","002099"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783264305737,"stockEarnings":[{"period":"1week","weight":0.0539},{"period":"1month","weight":-0.052},{"period":"3month","weight":-0.1968},{"period":"6month","weight":-0.1234},{"period":"1year","weight":-0.0666},{"period":"ytd","weight":-0.1234}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海翔药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34233人(较上一季度减少0.95%)","perCapita":"47230股","listingDate":"2006-12-26","address":"浙江省台州市椒江区外沙支路100号","registeredCapital":"161871万元","survey":" 浙江海翔药业股份有限公司的主营业务是原料药及医药中间体、染料及染颜料中间体的研发、生产和销售。公司的主要产品是蒽醌系列染料产品、中间体。公司企业技术中心被认定为“国家级企业技术中心”，拥有国家级博士后工作站，已承担完成国家级项目14项，省级项目35项，拥有国内发明专利67项、PCT专利4项，荣获浙江省级科技奖项11项。","listedPrice":11.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海翔药业,002099,海翔药业股票,海翔药业股票老虎,海翔药业股票老虎国际,海翔药业行情,海翔药业股票行情,海翔药业股价,海翔药业股市,海翔药业股票价格,海翔药业股票交易,海翔药业股票购买,海翔药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}